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Abstract
With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic
lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major
role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies.
ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or
refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/
venetoclax and other novel agents targeting the BCL-2 proteins.
Introduction
Tyrosine kinase inhibitors have ushered cancer treat-
ment to the era of targeted therapy [1–7]. Monoclonal
antibodies have revolutionized therapy for lymphoma
[8–13]. Cancer immunotherapy highlights the latest de-
velopment in clinical oncology [14–20]. In addition,
novel agents/vehicles, such as Bruton's tyrosine kinase
(BTK) inhibitors (e.g., ibrutinib) [21–24], chimeric T-cell
receptors (e.g., CART19) [25–29], NK cell-specific anti-
bodies (e.g., AFM13) [11, 30, 31], and CD19 BiTE anti-
bodies [32, 33], are in active clinical trials. It has been
well documented that B-cell lymphoma-2 (BCL-2) plays
a major role in cellular apoptosis and is a druggable target.
Several small molecule inhibitors of BCL-2 are in active
clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199)
has been granted breakthrough designation by FDA for
relapsed or refractory chronic lymphoid leukemia (CLL)
with 17p deletion. This review focused on the current
clinical development of a highly effective class of small
molecule BCL-2 inhibitors, including ABT-199/venetoclax.
BCL-2 gene and BCL-2 proteins
The BCL-2 gene was identified by cloning the break-
point of a t(14;18) translocation which was found fre-
quently in human B-cell lymphomas [34]. The BCL-2
gene resides on chromosome 18q21.33. The BCL-2
protein has 239 amino acids and a molecular weight of
26 KDa. It was the first identified major apoptotic regu-
lator. The ability to abrogate the death signal is a key
hallmark of cancer. BCL-2 plays a major role in tumori-
genesis and chemoresistance.
There are multiple proteins in the BCL-2 family [35]
(Fig. 1). The pro-death proteins include BCL-2-
associated X protein (BAX), BCL-2 antagonist/killer 1
(BAK), BCL-2-associated agonist of cell death (BAD),
BCL-2-like 11 (BIM), NOXA, and BCL-2 binding com-
ponent 3 (PUMA), whereas the pro-survival proteins
include BCL-2, BCL-XL, BCL-2-like 2 (BCL-w), mye-
loid cell leukemia sequence 1 (MCL-1), and BCL-2-
related protein A1 (BFL-1).
The roles of BCL-2 family proteins in cellular apoptosis
and oncogenesis have been extensively studied [35, 36].
Different members of the BCL-2 family of proteins have
pro- and anti-apoptotic functions, with their core function
being the regulation of mitochondrial outer membrane
permeability [37]. This in turn regulates the release of
pro-apoptotic factors such as the second mitochondrial
activator of caspases/direct inhibitor of apoptosis protein
binding protein with a low isoelectric point (Smac/DIA-
BLO), Omi/HtrA2 [38], apoptosis-inducing factor (AIF),
endonuclease G [39], and cytochrome-C [40, 41].
BCL-2 proteins can be classified into three subsets ac-
cording to the number of BCL-2 homology (BH) do-
mains [42] (Fig. 1). The presence of all four BH domains
is the hallmark of all anti-apoptotic BCL-2 proteins,
such as BCL-2, BCL-XL, and MCL-1, as mentioned
above. Pro-apoptotic BCL-2 family proteins typically
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have three BH domains and are further subdivided into
the BAX subset (example: BAX and BAK) and the BH3
subset [example: BH3 interacting domain death agonist
(Bid) and BAD] which only share homology at the BH3
domain [43, 44].
BCL-2 directly inhibits the influx of adenine nucleo-
tides through the outer mitochondrial membrane. This
reduces ATP hydrolysis and inhibits cytochrome-C re-
lease. BAX and BAK act through opposite mechanism
and are pro-apoptotic. Other members of the pro-
apoptotic pathway also function through the direct re-
lease of cytochrome-C or inhibition of BCL-2. Of note,
BCL-2 also maintains cells in the G0 phase in the ab-
sence of survival/growth factors—a potent oncogenic
mechanism.
BCL-2 inhibitors
By taking the advantage of the function of BH3 subset
pro-apoptotic proteins in promoting programed cell
death, multiple BH3 mimetics have been developed as
cancer therapeutics. They interact in an inhibitory man-
ner with the anti-apoptotic proteins BCL-2, BCL-XL,
and BCL-w.
ABT-737
ABT-737 is a small molecule inhibitor of BCL-2, BCL-
XL, and BCL-w [45]. ABT-737 showed in vitro activity
against lymphoma and small cell carcinoma cells. Subse-
quent in vitro studies showed activity against myeloma
[46, 47], acute leukemia [48, 49], and lymphoma. Further
studies confirmed in vivo activity of ABT-737 in mouse
xenograft models [50–53]. However, this compound has
low solubility and oral bioavailability.
ABT-263 (navitoclax)
ABT-263 (navitoclax) is another potent small molecule
inhibitor of BCL-2, BCL-XL, and BCL-w. It was tested
on multiple cell lines in vitro and in xenograft models
[54] and shown to have significant activity against acute
lymphoblastic leukemia (ALL) cell lines. Subsequent
studies showed in vitro activity against leukemia and
lymphoma cells [55] with efficacy replicated in mouse
models for pediatric ALL [56], non-Hodgkin’s lymphoma
[57], and myeloma [58].
Subsequently, phase I trials of ABT-263 were carried
out in lymphoid malignancies. The first trial to evaluate
ABT-263/navitoclax studied two different dosing sched-
ules in 55 patients with relapsed/refractory (R/R) lymph-
oid malignancies [59]. The first dosing evaluation
consisted of navitoclax given orally once a day at dose
ranges from 10 to 440 mg from days 1 to 14 in a 21-day
cycle (intermittent schedule). The second dosing schedule
consisted of navitoclax once daily at dose ranges from 200
to 425 mg for days 1–21 in a 21-day cycle (continuous
schedule). Due to significant thrombocytopenia reported
from earlier trials, a loading dose of 150 mg daily for 7–
14 days was used for the continuous dosing. The maximal
tolerated dose was noted to be 315 mg for the intermittent
schedule and 325 mg for the continuous schedule. In the
intermittent schedule regimen, at 440 mg, grade III trans-
aminitis and grade IV thrombocytopenia were observed.
In the continuous-schedule regimen, grade III transamini-
tis and gastrointestinal bleed were observed [59]. A phase
IIa study is currently ongoing.
Another phase I trial evaluated intermittent and con-
tinuous dosing in 29 patients with relapsed/refractory
CLL [60]. The patients received oral navitoclax daily
Fig. 1 Structures of BCL-2 family proteins. According to the BH domains, the BCL-2 family proteins can be categorized into three subsets. BH4-containing
BCL-2 and related BCL-XL, BCL-w, MCL-1, A1(BFL-1), and Boo are anti-apoptotic proteins. The remaining two subsets (BAX and Bik subgroups) do not have
a BH4 domain and are pro-apoptotic proteins
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either for 14 days (10, 110, 200, or 250 mg/day; n = 15)
or 21 days (125, 200, 250, or 300 mg/day; n = 14) of each
21-day cycle. Dose escalation was done according to a
continual reassessment methodology. The phase 2 dos-
ing was determined to be 250 mg daily in a continuous
dosing schedule. The dose-limiting toxicity (DLT) was
mainly due to dose-related thrombocytopenia. Efficacy
data showed partial response in 9 (31 %) of the patients
and stable disease in 18 patients (8 with durable SD >
6 months, 7 > 12 months). Reduction in lymphocytosis
was seen in 50 % of the evaluable patients. Median
progression-free survival was 25 months. Navitoclax
was found to have activity in high-risk patients with
fludarabine-refractory disease, bulky adenopathy, and
del(17p) CLL.
ABT-199 (venetoclax, RG7601, GDC-0199)
Preclinical studies of ABT-199
The dose-limiting severe thrombocytopenia from ABT-
263/navitoclax quenched the enthusiasm for further
clinical development of this compound. Preclinical stud-
ies of ABT-737 also revealed decreased platelet survival
[61]. A seminal study by Mason et al. [62] had previously
highlighted the importance of BCL-XL in platelet sur-
vival, its role in the pro-apoptotic activity of BAK, and a
gradual reduction in BCL-XL levels culminating in the
apoptosis of senescent platelets. The term molecular
clock was used to describe this temporal switch from
anti-apoptosis to pro-apoptosis [62]. Therefore, BCL-XL
inhibition could speed up this molecular clock and lead
to decreased platelet survival—the mechanism impli-
cated in ABT-737/ABT-263-induced thrombocytopenia.
The need to develop a BCL-2 inhibitor sparing BCL-
XL and platelets sparked the discovery and development
of ABT-199 (venetoclax) [63]. X-ray complex-based
structures determined the presence of high-affinity inter-
actions in two hydrophobic pockets in the three-
dimensional structure of anti-apoptotic BCL-2 proteins.
These hot spots, named P2 and P4, bind to the 1-
chloro-4-(4,4-dimethylcyclohex-1-enyl)benzene and the
thiophenyl moiety of navitoclax, respectively. Along with
the hydrophobic interactions, electrostatic interactions
between arginine residues (on anti-apoptotic proteins)
and aspartate residues (on pro-apoptotic molecules)
were also underscored. Through reverse engineering of
navitoclax, structural modifications were made so that a
new molecule was created to have similar hydrophobic
interaction but different electrostatic interaction with
Arg103 (specific to BCL-2 since BCL-XL has Glu96).
This led to the discovery of BCL-2 binding molecule,
ABT-199.
ABT-199 (venetoclax) represents the first-in-class, se-
lective, oral BCL-2 inhibitor sparing platelets [63]. It
showed sub-nanomolar affinity to BCL-2 (Ki < 0.010 nM)
with antitumor activity against non-Hodgkin’s lymph-
oma (NHL) [63], CLL [64], and acute leukemias [65, 66]
in vitro. In vivo mouse xenograft studies showed activity
against aggressive (Myc+) lymphomas [67] as well as
acute leukemia [68].
BCL-2 over-expression plays a central role in follicular
lymphoma (FL). In vitro studies were done to characterize
the effects of ABT-199 in the t(14;18)+ FL cell lines WSU-
FSCCL and FC-TxFL2 and in primary FL cells [69]. JNK
kinase phosphorylation and inactivation as well as sub-
stantial decrease of mitochondrial potential in FC-TxFL2
cells were induced by ABT-199. Similar expression levels
were seen in the anti-apoptotic (such as BCL-2, BCL-XL,
MCL-1) and pro-apoptotic proteins (such as BAX,
PUMA, BAK, BAD, NOXA, Bid, Bok) in both cell lines.
No significant change was seen in these proteins upon
ABT-199 treatment. In this study, the ABT-199 resistant
cell line was established. Increased levels of MCL-1 and el-
evated phosphorylation of BCL-2 on T56 and of AKT on
S473 were demonstrated. In addition, increased autophagy
was shown in comparison to parental cells. It was also
demonstrated in this study that the combination of two
epigenetic agents, decitabine and vorinostat, was able to
overcome ABT-199 resistance. Even though ABT-199
should be theoretically active in FL as a BH3 mimetic, ac-
tivity in patients with FL has not been as dramatic as has
been observed for CLL. Acquired resistance developed
easily in the in vivo study in the xenograft model, which
may explain the relatively higher failure possibility in FL
than in CLL.
ABT-199 was studied in combinations with tyrosine
kinase inhibitors (TKIs), including imatinib, nilotinib,
dasatinib, or ponatinib, in cells from six patients with
blast-crisis chronic myeloid leukemia (CML) [70]. All six
patients were resistant to TKIs, three of them with
T315I mutation. This study further revealed in a CML
mouse model that ABT-199 alone or in combination
was better than nilotinib in eradicating CML stem cells
in vivo.
A combination of ibrutinib and ABT-199 was also
studied in mantle cell lymphoma (MCL) and CLL [71].
The ibrutinib and ABT-199 combination substantially
induced apoptosis of primary cells from MCL and CLL
patients compared to each single agent alone (combo:
23 %, ibrutinib: 3.8 %, ABT-199: 3.0 %). When BCL-2
and BTK target genes as well as emergent genes were
characterized using a protein-protein network inter-
action model, synergistic activation of apoptosis genes of
p53 and BIM was revealed. Little off-target effect was
seen with the combination nor with individual drugs on
normal peripheral T cells [71].
Selinexor (KPT-330), a first-in-class selective inhibitor
of nuclear export (SINE) agent, has been shown to have
antiproliferative and pro-apoptotic activities against
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MCL and other cancer cells [72–76]. A combination of
ABT-199 and selinexor was studied in MCL cell lines
[77]. The combination demonstrated synergistic anti-
proliferative effects through inhibition of mTOR signal-
ing, downregulation of ribosomal biosynthesis, and induction
of mitochondria-mediated apoptosis.
MCL-1, an anti-apoptotic protein, is one of the main
targets of homoharringtonine (HHT) and omacetaxine,
both of which have been in clinical applications [78, 79].
To test the dual inhibition of BCL-2 and MCL-1, HHT
and ABT-199 were combined and tested in seven diffuse
large B-cell lymphoma cell lines [80]. The study con-
firmed decreased expression of MCL-1 protein in all the
cell lines. It was also demonstrated that high expression
of BCL-2 positively correlated with sensitivity to ABT-
199, irrespective of expression levels of BCL-XL and
MCL-1. BCL-2 and BCL-XL expression levels negatively
correlated with sensitivity to HHT. However, the expres-
sion level of MCL-1 did not correlate with sensitivity to
HHT.
Clinical studies of ABT-199
Preliminary data from a phase I trial of ABT-199 showed
an overall response rate (ORR) of 84 % in 56 patients
with relapsed/refractory CLL [81] (Table 1). At a median
follow-up of 10.9 months, a complete response (CR) of
23 % and partial response (PR) of 61 % were achieved.
ABT-199 dosages of 150–1200 mg given once on days 3
or 7 followed by once daily were used. Diarrhea (46 %),
neutropenia (43 %), fatigue (34 %), upper respiratory
tract infection (29 %), and cough (25 %) were the most
common side effects. Dose-limiting toxicities (DLTs)
were reported to include six tumor lysis syndromes
(TLSs), one sudden death, and one grade IV neutro-
penia. TLS complication is now better prevented with a
lead-in dose-escalation step [82].
The latest update showed an ORR of 79 % in 84 pa-
tients with relapsed/refractory (R/R) CLL with median
duration of response of 20.5 months. The most common
adverse events (AEs) remained similar—neutropenia
(39 %), diarrhea (36 %), nausea (35 %), upper respiratory
tract infection (31 %), and fatigue (27 %). Grade 3/4 AEs
included neutropenia, anemia, TLS (8 % including one
death), and thrombocytopenia (7 %) [83].
A phase Ia trial of ABT-199 in R/R NHL used continu-
ous daily dosing of 200–900 mg. A single dose was
administered on day 7 followed by a lead-in period with
stepwise upward titration over 2–3 weeks. An ORR of
48 % was achieved in 40 patients with responses across
various NHL subtypes; the most common AEs included
nausea (34 %), upper respiratory tract infection (27 %),
diarrhea (25 %), and fatigue (21 %). DLTs included sub-
clinical TLS (based on laboratory criteria) [84].
The single-agent ABT-199 was studied in a phase 2,
open-label, multicenter trial in patients (pts) with high-
risk R/R AML and in untreated patients who were unfit
for intensive chemotherapy [85]. The study allowed
intra-patient dose escalation when a patient received
20 mg ABT-199 on week (Wk) 1 day 1. Daily escalation
was implemented to target a final dose of 800 mg on day
6 and daily thereafter. Those patients without a CR or
CR with incomplete hematological recovery (CRi) at the
first scheduled assessment (end of Wk 4) were able to
escalate to 1200 mg. Of the 32 pts enrolled, 30 (93.8 %)
had R/R disease, 12 (37.5 %) had a history of myelodys-
plastic syndrome, and 2 (6 %) had a history of myeloprolif-
erative neoplasms. The patients were heavily pretreated.
Fourteen (44 %) had progressed through at least three
prior treatments and 22 (69 %) had failed hypomethylating
agents. The most common treatment emergent AEs
(TEAEs) (in ≥25 % of patients) were nausea, diarrhea, fa-
tigue, neutropenia, and vomiting. Severe AEs were febrile
neutropenia, anemia, and pneumonia. One CR and four
CRi were seen at first assessment. Of the five patients with
CR/CRi, three had IDH mutation. The ORR was 15.5 %
(5/32). Therefore, ABT-199 appears to have considerable
single-agent clinical activity in patients with poor progno-
sis R/R AML. It is worthy of note that patients with IDH
mutation may be particularly sensitive to ABT-199.
ABT-199 in combination regimens
A phase Ib trial of ABT-199 in combination with rituxi-
mab (R) in patients with relapsed/refractory CLL en-
rolled 37 patients. Rituximab dosage was 375 mg/m2
titrated to 500 mg/m2 monthly for 6 months. ABT-199
dosages began at 20 mg titrated weekly to 200–600 mg.
Eighteen patients had completed therapy with 39 %
showing CR and 39 % achieving PR (ORR 78 %). Most
common AEs included neutropenia (43 %), nausea
(38 %), and diarrhea (30 %). DLTs were reported to be
thrombocytopenia and hemophagocytic syndrome [86].
An update of the study was reported at 2014 ASH which
included 49 pts in five dose-escalation cohorts (n = 41)
and one safety expansion cohort (n = 8) [87]. The pa-
tients were heavily pretreated, with a median number of
prior therapies at 3 (range 1–10). Thirteen patients
Table 1 Single agent clinical trials of venetoclax/ABT-199
Clinical trials Diseases Responses References
Phase I R/R CLL ORR—79 % 81, 83
Phase Ia R/R NHL ORR—48 % 84
Phase II R/R AML ORR—15 % 85
New AML
R/R relapsed/refractory, ORR overall response rate, CLL chronic lymphoid
leukemia, NHL non-Hodgkin’s lymphoma, AML acute myeloid leukemia
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(27 %) were refractory to fludarabine and nine (18 %)
were R-refractory. Among them also included nine
(18 %) with del(17p). The ORR was 88 %, with 11 (32 %)
achieving a CR/CRi and 20 (56 %) achieving PR in the
34 pts who were evaluable for response in dose-
escalation cohorts. The recommended phase 2 dose
(RPTD) of ABT-199 is 400 mg daily. The combination
of ABT-199 and R was well tolerated and induced an
ORR of 86 % with 31 % CRs in pts with CLL/SLL [87].
A phase 3 trial comparing ABT-199 and R versus benda-
mustine and R in pts with previously treated CLL is un-
derway (NCT02005471) [88] (Table 2).
A phase I, open-label, multicenter study of ABT-199
in combination with bendamustine (B) and rituximab
(R) was reported in patients with R/R NHL [89]. In the
dose-escalation portion of the study, ABT-199 doses
ranged from 50 to 400 mg. Dosing schedules were as fol-
lows: 3, 7, and 28 days/cycle in each 28-day cycle. Stand-
ard BR treatment for six cycles were given as the
following: B (2 days/cycle, 90 mg/m2) and R (1 day/cycle,
375 mg/m2). ABT-199 followed by BR was administered
on day 1 of cycles 4–6. Upon completion of BR treat-
ment, ABT-199 was continued as monotherapy. At the
last update in July 2014, 26 patients have received ABT-
199 in combination with BR. Fifteen (57.7 %) patients
had follicular lymphoma (FL), eight (30.8 %) had diffuse
large B-cell lymphoma (DLBCL), and three (11.5 %) had
marginal zone lymphoma (MZL). Out of 26 patients, 11
(42 %) had completed six cycles of BR treatment. The
most common TEAEs included nausea (65.4 %), anemia
and neutropenia (each in 42.3 %), diarrhea (38.5 %), and
thrombocytopenia (34.6 %). Severe AEs included neutro-
penia (26.9 %) and anemia and thrombocytopenia (each
in 19.2 %). DLTs included febrile neutropenia and
thrombocytopenia. Dosing schedule was modified to
7 days/cycle for patients in cohort 6. G-CSF prophylaxis
was added. No DLTs were observed in the subsequent
cohorts. The overall response rate (CR + PR) for ABT-
199 + BR was 61.5 % (16/26) for all patients, 73.3 % (11/
15) for patients with FL, and 37.5 % (3/8) for patients
with DLBCL. Further enrollment employed 400 mg
ABT-199 with re-examination of a 28-day cycle schedule
with G-CSF prophylaxis in heavily pretreated patients. A
phase 2 study (NCT02187861; BO29337) of ABT-199 +
BR in R/R FL was planned.
Another phase 1b study evaluated the MTD of
ABT-199 in combination with BR in R/R or previ-
ously untreated patients (pts) with CLL [90]. Dosages
ranged from 100 to 600 mg/day of ABT-199 using a
3 + 3 dose-escalation design. The study also incorpo-
rated a gradual dose ramp-up of ABT-199 to reduce
the risk of TLS. A preliminary report summarized the
data on six pts with R/R CLL, including three pts in
the 100-mg cohort and three pts in the 200-mg co-
hort. TLS risks were considered for risk stratification.
The most common AE was anemia with most grade 3
AEs being hematological toxicities. There was no TLS
as a result of the ramp-up dosing of ABT-199 and
prophylactic measures. Dose escalation in R/R pts was
ongoing. Enrollment of previously untreated pts was
also planned.
In another phase Ib study, ABT-199 was combined
with obinutuzumab in R/R or previously untreated pa-
tients with CLL [91]. ABT-199 dosage ranged from 100
to 600 mg/day. A gradual dose ramp-up of ABT-199 and
staggering of the two agents were applied to reduce the
risk of tumor lysis syndrome (TLS). After completing
combination therapy, ABT-199 was continued until dis-
ease progression. Nine patients were enrolled in the pre-
liminary report, including three in the 100-mg ABT-199
dosing cohort and six in the 200-mg dosing cohort. La-
boratory TLS (characterized by asymptomatic laboratory
abnormalities in potassium and phosphate) was observed
in 1 of the first 3 patients. One patient had a dose reduc-
tion from 100 to 50 mg per day due to prolonged
neutropenia but subsequently completed six cycles of
combination treatment. For obinutuzumab, infusion-
related reactions were seen but limited to the first infu-
sion. The combination was safe and well tolerated. No
clinical TLS was observed in these nine patients. Dose
escalation of ABT-199 was done in those R/R patients at
400 mg/day.
The phase II trial of ABT-199 in 17p (-) relapsed/re-
fractory CLL patients (NCT01889186 [92]) is underway.
Apart from this, multiple studies evaluating ABT-199
in multiple myeloma (NCT01794507, NCT01794520),
CLL (NCT02242942, NCT01685892, NCT01671904,
NCT02427451, NCT02141282, NCT02401503), and
NHL (NCT02187861, NCT02558816, NCT02055820,
NCT02471391, NCT02419560, NCT01594229) are cur-
rently active.
Table 2 Clinical trials of venetoclax/ABT-199 in combination
regimens
Clinical trials Regimens Diseases Responses References
Phase Ib V + R R/R CLL ORR—88 % 86, 87
CR/CRi—32 %
PR—56 %
Phase I V + BR R/R NHL ORR—61.5 % 89
Phase Ib V + BR R/R CLL Not reported 90
Untreated CLL
Phase Ib V + O R/R CLL Not reported 91
Untreated CLL
R/R relapsed/refractory, ORR overall response rate, CLL chronic lymphoid
leukemia, NHL non-Hodgkin’s lymphoma, AML acute myeloid leukemia. For
regimens: V venetoclax, R rituximab, B bendamustine, O obinutuzumab
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Conclusion and future directions
ABT-199/venetoclax showed high response rate as a sin-
gle agent in refractory/relapsed CLL. In particular, high
CR rate was reported in refractory/relapsed CLL (29 %
as single agent, 39 % in combination with rituximab).
This is quite different from ibrutinib, which acts slowly
and rarely induces CR as a single agent in this popula-
tion of patients. Resistance in lymphoid cells to ABT-
199 has been reported [93]. Combination regimens to
counteract these mechanisms are being evaluated [94,
95]. The lack of BCL-XL inhibition with ABT-199 signifi-
cantly reduced the dose-limiting thrombocytopenia.
Since BCL-2 plays a major role as an anti-apoptotic pro-
tein in multiple hematological malignancies, ABT-199
has the potential to be effective as a single agent or in
combination with other agents toward a broad spectrum
of hematological malignancies. ABT-199 therefore may
lead to the shift of current treatment paradigms in
hematological cancers.
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